Xocova (ensitrelvir) / Shionogi 
Welcome,         Profile    Billing    Logout  

8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xocova (ensitrelvir) / Shionogi
SCORPIO-HR, NCT05305547: A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19

Completed
3
2093
Europe, Japan, US, RoW
S-217622, Placebo
Shionogi, National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2 Infection
01/24
05/24
SCORPIO-PEP, NCT05897541: Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

Recruiting
3
2200
Japan, US
S-217622, Placebo
Shionogi
SARS-CoV-2 Infection
09/24
09/24
NCT05605093: Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

Recruiting
3
1500
Europe, Japan, US, RoW
Shionogi Protease Inhibitor (S-217622), ensitrelvir, placebo
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
07/25
07/25
PREVAIL-LC, NCT06161688: Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID

Recruiting
2
40
US
Ensitrelvir, ensitrelvir fumaric acid, Placebo
Timothy Henrich, Shionogi Inc.
Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19
03/25
12/25
PLATCOV, NCT05041907: Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19

Recruiting
2
3800
RoW
Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Nitazoxanide, Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™), Hydroxychloroquine, No treatment, Monoclonal antibodies, Fluoxetine, Molnupiravir, Sotrovimab, Ensitrelvir, Favipiravir, Ivermectin, Remdesivir, Atilotrelvir/ritonavir, Metformin, Nirmatrelvir/ritonavir, Nirmatrelvir
University of Oxford
COVID-19
01/27
01/27
NCT05363215: A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants

Completed
1
32
US
S-217622
Shionogi
Renal Impairment
04/23
04/23
NCT05409911: A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants

Completed
1
25
US
S-217622
Shionogi
Hepatic Impairment
04/23
04/23
ChiCTR2300071600: Pharmacokinetic Study of Desetivir Fumarate Tablets (110mg) in Chinese Healthy Subjects

Not yet recruiting
1
96
 
DEXAMETHERVIR FUMARATE TABLETS 110 MG ;Entamivir Fumarate Tablets (trade name: XOCOVA, strength: 125 mg)
Wannan Medical College Yijishan Hospital; Wannan Medical College Yijishan Hospital, Horizontal topic
SARS-CoV-2
 
 

Download Options